KPWS
NTLA icon

Kestra Private Wealth Services’s Intellia Therapeutics NTLA Stock Holding History

Kestra Private Wealth Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,208
Closed -$608K – 1784
2025
Q3 		$608K Buy
+35,208
New +$434K 0.01% 1009
2021
Q3 		– Sell
-1,789
Closed -$290K – 952
2021
Q2 		$290K Sell
1,789
-1,300
-42% -$101K 0.02% 692
2021
Q1 		$248K Buy
+3,089
New +$207K 0.02% 669

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kestra Private Wealth Services's NTLA Position: Q4 2025 in Review

Kestra Private Wealth Services sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 35,208 shares — an estimated $608K sold.

Kestra Private Wealth Services first reported a position in NTLA in Q1 2021 and held it in 3 quarters. The position peaked at $608K in Q3 2025. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Kestra Private Wealth Services reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kestra Private Wealth Services sold 35,208 Intellia Therapeutics shares in Q4 2025, an estimated $608K.
  • Kestra Private Wealth Services first reported a position in Intellia Therapeutics in Q1 2021 and held it in 3 quarters.
  • Kestra Private Wealth Services's Intellia Therapeutics position peaked at $608K in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Kestra Private Wealth Services's 13F filing for Q4 2025, filed 29 Jan 2026.